Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.

NCT00450580 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00450580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00450580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2008
Enrollment
212 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection, infection, human immunodeficiency virus i